Flagship Pioneering, LLC reported 5 positions worth $1.54B for the quarter ended Jun 30, 2026, up 32.6% on the prior quarter. It opened 0 new positions, added to 0, trimmed 0 and exited 0. Its largest holding is Generate Biomedicines, Inc. at 68.7% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
No positions were added to this quarter.
No positions were reduced this quarter.
No new positions this quarter.
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | GENB Generate Biomedicines, Inc. | Healthcare | 62.67M | $1.06B | 68.66% | 0 | 0.0% | Unchanged | 48.86% |
| 2 | MRNA Moderna, Inc. | Healthcare | 4.63M | $324.39M | 21.07% | 0 | 0.0% | Unchanged | 1.16% |
| 3 | SANA Sana Biotechnology, Inc. | Healthcare | 25.00M | $87.26M | 5.67% | 0 | 0.0% | Unchanged | 8.35% |
| 4 | FHTX Foghorn Therapeutics Inc. | Healthcare | 12.67M | $61.85M | 4.02% | 0 | 0.0% | Unchanged | 17.94% |
| 5 | MCRB Seres Therapeutics, Inc. | Healthcare | 1.16M | $9.12M | 0.592% | 0 | 0.0% | Unchanged | 11.76% |
Tip. Select a row to see that position’s full history at Flagship Pioneering.
As of its Q2 2026 13F filing, Flagship Pioneering, LLC’s five largest positions were Generate Biomedicines, Inc. (GENB) at 68.7%, Moderna, Inc. (MRNA) at 21.1%, Sana Biotechnology, Inc. (SANA) at 5.7%, Foghorn Therapeutics Inc. (FHTX) at 4.0%, Seres Therapeutics, Inc. (MCRB) at 0.6% of the reported portfolio.
Flagship Pioneering, LLC reported a 13F portfolio worth $1.54B across 5 positions for Q2 2026. That is up 32.6% from the previous quarter.
From the Form 13F-HR reports Flagship Pioneering, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.